Akebia Therapeutics, Inc. (AKBA)

From the record

Akebia Therapeutics, Inc.'s filings since 2017 show 7 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2026-10-23); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2023-08-10) (its current reports).

From the record

Akebia Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $2 million in fiscal 2016 to $236 million in fiscal 2025, up 75% a year; it rose in 5 of 9 years; the deepest fall was 52% from fiscal 2019 to fiscal 2024; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Akebia Therapeutics, Inc.'s diluted share count grew about 12.0% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 16 sales (16 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $87 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Akebia Therapeutics, Inc. lost about 16 cents for every dollar of shareholders' money, and gross profitability: its products earned about 52 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 91 cents per dollar of assets, and net share issuance: its share count grew 21.9% over the year (the filed statements).

From the record

Akebia Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $236 million in fiscal 2025 ranks in the top 27% by size; a net margin of -2.3% ranks in the top 25%; revenue growth of -6.9% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).

From the record

Akebia Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Butler, John P. (CEO and President, as filed), filing under that title since 2014-03-19, 12.7 years (top 9% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 47%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 32%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Akebia Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $185 million against debt of $48 million leaves 36.3% of its assets as net cash, top 40% of its family; cash from operations less capital spending is 28.7% of revenue (top 8%); a gross margin of 83.3% (top 28%); research spending of 26.4% of revenue (bottom 32%) (its annual report).

From the record

Akebia Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -6.9% a year over the last three filed years against 75% over all 10, slowing (bottom 6% of its family); the newest year grew 47.5% (top 27%); research spending grew -21.7% a year (bottom 18%); capital spending grew 36.7% a year (top 18%) (its annual reports). Akebia Therapeutics, Inc. reported 3 product lines in fiscal 2025: Auryxia at $182 million (77%), Vafseo at $46 million (19%), License Collaboration and Other Revenue at $9 million (4%); 2 of 2 grew against the year before (its annual report).

From the record

Akebia Therapeutics, Inc.'s newest year against its own record: revenue of $236 million in fiscal 2025 came in 99.2% above the $119 million its prior three years' pace pointed to (top 15% of its family); net income of $5 million against a prior three-year average of $72 million (top 18%); a net margin of -2.3% against -34.1% before (top 42%) (its annual reports).